<DOC>
	<DOCNO>NCT01607385</DOCNO>
	<brief_summary>A single blind , randomize , placebo-controlled , dose escalate study evaluate safety , tolerability , pharmacokinetic pharmacodynamic parameter repeat dos GSK2330672 healthy volunteer , give alone single day dose GSK1614235</brief_summary>
	<brief_title>A Study Evaluate Safety , Tolerability , Pharmacokinetic Single Day Dosing With GSK1614235 .</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Healthy determine responsible experienced physician , base medical evaluation include medical history , physical examination , laboratory test cardiac monitoring . A subject clinical abnormality laboratory parameter outside reference range population study may include Investigator GSK Medical Monitor agree find unlikely introduce additional risk factor interfere study procedure . Laboratory assessment may repeat outside normal range . The Investigator may interpret screen vital sign data base subject 's age , physical state level fitness . Subjects vital sign reading marginally outside normal range may include study Investigator 's opinion value clinically significant present safety risk affect study assessment . Capable give write informed consent , include compliance requirement restriction list consent form . Subjects must understand aim , investigational procedure possible consequence study must able understand comply protocol requirement , instruction protocolstated restriction . Male female 18 60 year age inclusive , time signing informed consent . A female subject eligible participate : Nonchildbearing potential define premenopausal female document tubal ligation hysterectomy ; postmenopausal define 12 month spontaneous amenorrhea . In questionable case , blood sample simultaneous follicle stimulate hormone great 40 MlU/ml estradiol le 40 pg/ml ( le 140 pmol/L ) confirmatory absence clear postmenopausal history ; Females hormone replacement therapy must discontinue hormone replacement therapy allow confirmation postmenopausal status prior study enrollment . For form hormone replacement therapy , least 24 week elapse cessation therapy blood draw ; interval depend type dosage hormone replacement therapy . Following confirmation postmenopausal status , resume use hormone replacement therapy study . Body mass index within range 19 32kg/m2 ( inclusive ) . ALT , alkaline phosphatase bilirubin great 1.5xULN ( isolate bilirubin great 1.5xULN acceptable bilirubin fractionate direct bilirubin le 35 % . Current chronic history inflammatory bowel disease , chronic diarrhea , Crohn 's disease malabsorption syndromes . Current chronic history cholelithiasis , inflammatory gall bladder disease , cholestatic liver injury , cholecystectomy . Current chronic history liver disease , know hepatic abnormality ( exception Gilbert 's syndrome ) . Fecal occult blood positive test screening . Triglycerides great 250mg/dL . History chronic acute pancreatitis . Mean QTc great equal 450msec three tracing obtain least 5 minute apart . A positive prestudy Hepatitis B surface antigen positive Hepatitis C antibody result within 3 month screen . A positive test HIV antibody . A positive prestudy drug/alcohol screen . A minimum list drug screen include amphetamine , barbiturate , cocaine , opiates , cannabinoids benzodiazepine . History regular alcohol consumption within 6 month study define average weekly intake great 14 drink male great 7 drink female . One drink equivalent 12g alcohol : 12 ounce ( 360mL ) beer , 5 ounce ( 150mL ) wine 1.5 ounce ( 45mL ) 80 proof distil spirit . The subject participate clinical trial receive investigational product within following time period prior first dose day current study : 30 day 5 halflives investigational product ( whichever longer ) . Exposure four new chemical entity within 12 month prior first dose day . Unable refrain use prescription nonprescription drug , include vitamin , herbal dietary supplement ( include St John 's Wort ) within 7 day ( 14 day drug potential enzyme inducer ) 5 halflives ( whichever longer ) prior first dose study medication , unless opinion Investigator GSK Medical Monitor medication interfere study procedure compromise subject safety . History sensitivity study medication , component thereof history drug allergy , opinion Investigator GSK Medical Monitor , contraindicate participation . Where participation study would result donation blood blood product excess 500mL within 56day period . History sensitivity heparin heparininduced thrombocytopenia . Urinary cotinine level indicative smoke history regular use tobacco nicotinecontaining product within 6 month prior screen . Subject either immediate family member participate investigator , study coordinator , employee investigator ; member staff conduct study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>pharmacokinetic</keyword>
	<keyword>intestinal bile acid transporter inhibitor</keyword>
	<keyword>GSK2330672</keyword>
	<keyword>pharmacodynamic</keyword>
	<keyword>GSK1614235</keyword>
	<keyword>dose escalation</keyword>
</DOC>